Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nonspecific effect of Mycograb on amphotericin B MIC.

Literature DB >> 22508314

Nonspecific effect of Mycograb on amphotericin B MIC.

D L Richie¹, M A Ghannoum, N Isham, K V Thompson, N S Ryder.

Abstract

Mycograb C28Y is a recombinant human antibody fragment thought to target HSP-90 and potentiate amphotericin B (AMB). Absence of in vivo efficacy led us to reevaluate its in vitro activity. Interactions between AMB and Mycograb were investigated using a checkerboard design. Addition of Mycograb or various unrelated proteins, including human serum, resulted in similar decreases in the MIC of AMB. Potentiation of AMB by Mycograb appears to be a nonspecific protein effect.

Entities: Chemical Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22508314 PMCID： PMC3393390 DOI： 10.1128/AAC.00435-12

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

8 in total

1. Influence of human serum on antifungal pharmacodynamics with Candida albicans.

Authors: G G Zhanel; D G Saunders; D J Hoban; J A Karlowsky
Journal: Antimicrob Agents Chemother Date: 2001-07 Impact factor: 5.191

2. Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages.

Authors: Y Minn; E Brummer; D A Stevens
Journal: Mycopathologia Date: 1997 Impact factor: 2.574

3. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.

Authors: Arnold Louie; Daniel S Stein; Julia Z Zack; Weiguo Liu; Haley Conde; Christine Fregeau; Brian D Vanscoy; George L Drusano
Journal: Antimicrob Agents Chemother Date: 2011-04-18 Impact factor: 5.191

4. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.

Authors: Lucy Nooney; Ruth C Matthews; James P Burnie
Journal: Diagn Microbiol Infect Dis Date: 2005-01 Impact factor: 2.803

5. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

Authors: Jan Pachl; Petr Svoboda; Frédérique Jacobs; Koenraad Vandewoude; Ben van der Hoven; Peter Spronk; Gary Masterson; Manu Malbrain; Mickael Aoun; Jorge Garbino; Jukka Takala; Lubos Drgona; James Burnie; Ruth Matthews
Journal: Clin Infect Dis Date: 2006-04-12 Impact factor: 9.079

6. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors: E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal: Antimicrob Agents Chemother Date: 1991-11 Impact factor: 5.191

7. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors: Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal: Antimicrob Agents Chemother Date: 2003-07 Impact factor: 5.191

Review 8. Monoclonal antibody-based therapies for microbial diseases.

Authors: Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal: Vaccine Date: 2009-12-30 Impact factor: 3.641

8 in total

11 in total

10. Biological and Physico-Chemical Characteristics of Arginine-Rich Peptide Gemini Surfactants with Lysine and Cystine Spacers.

Authors: Damian Neubauer; Maciej Jaśkiewicz; Marta Bauer; Agata Olejniczak-Kęder; Emilia Sikorska; Karol Sikora; Wojciech Kamysz
Journal: Int J Mol Sci Date: 2021-03-24 Impact factor: 5.923

Nonspecific effect of Mycograb on amphotericin B MIC.

1. Influence of human serum on antifungal pharmacodynamics with Candida albicans.

2. Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages.

3. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.

4. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.

5. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

6. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

7. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Review 8. Monoclonal antibody-based therapies for microbial diseases.

Review 1. Emerging drugs and vaccines for candidemia.

Review 2. The protective role of immunoglobulins in fungal infections and inflammation.

Review 3. Candida albicans Heat Shock Proteins and Hsps-Associated Signaling Pathways as Potential Antifungal Targets.

Review 4. Antimicrobial Activity and Resistance: Influencing Factors.

Review 5. Immunomodulation as Therapy for Fungal Infection: Are We Closer?

Review 6. Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.

Review 7. Human monoclonal antibody-based therapy in the treatment of invasive candidiasis.

Review 8. Candida infections and their prevention.

Review 9. The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future.

10. Biological and Physico-Chemical Characteristics of Arginine-Rich Peptide Gemini Surfactants with Lysine and Cystine Spacers.